Correlations between concentrations of interleukin (IL)-17A, IL-17B and IL-17F, and endothelial cells and proangiogenic cytokines in systemic lupus erythematosus patients

European Cytokine Network

Volumn 24, Issue 1, 2013, Pages 60-68

  Robak, Ewa ^a   Kulczycka Siennicka, Lilianna ^a   Gerlicz, Zofia ^a   Kierstan, Monika ^a   Korycka Wolowiec, Anna ^a   Sysa Jedrzejowska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Circulating endothelial cells; IL 17A; IL 17B; Il 17F; SLE

Indexed keywords

C REACTIVE PROTEIN; CD133 ANTIGEN; CD146 ANTIGEN; CD31 ANTIGEN; ENDOGLIN; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 23; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANGIOGENESIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE ACTIVITY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; SYSTEMIC LUPUS ERYTHEMATOSUS;

CIRCULATING ENDOTHELIAL CELLS; IL-17A; IL-17B; IL-17F; SLE;

ADULT; ANGIOGENESIS INDUCING AGENTS; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE PROTEINS; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84878073363     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2013.0330     Document Type: Article

References (54)

1. Nalbandian A, Crispín JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009; 157: 209.
2. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 2009; 5: 325.
3. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology 2009; 48: 602.
4. Stamp LK, James MJ, Cleland LG. Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol Cell Biol 2004; 82: 1.
5. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008; 10: 206.
6. Ryu S, Lee JH, Kim SI. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006; 25: 16.
7. Honorati MC, Neri S, Cattini L, Facchini A. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 2006; 14: 345.
8. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620.
9. Ryu S, Lee JH, Kim SI. IL-17 increased the production of vascular endothelial growth factor in rheumatoid arthritis synoviocytes. Clin Rheumatol 2006; 25: 16.
10. Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175: 6177.
11. Benchetrit F, Ciree A, Vives V, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99: 2114.
12. Kryczek I, Wei S, Szeliga W, et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009; 114: 357.
13. Sanders AJ, Guo X, Mason MD, Jiang WG. IL-17B Can Impact on Endothelial Cellular Traits Linked to Tumour Angiogenesis. J Oncol 2010; 2010: 817.
14. Xie Y, Sheng W, Xiang J, et al. Interleukin-17F suppresses hepatocarcinoma cell growth via inhibition of tumor angiogenesis. Cancer Invest 2010; 28: 598.
15. Starnes R, Robertson MJ, Sledge G, et al. IL-17F, a novel ecytokine selectively expressem in activated T Cells and monocytes, regulates angiogenesis and endothelial cell production. J Immunol 2001; 167: 4137.
16. Shi Y, Ullrich SJ, Zhang J, et al. A novel cytokine receptorligand pair: identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 2000; 275: 19167.
17. Li H, Chen J, Huang A, et al. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci USA 2000; 97: 773.
18. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin- 17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155.
19. Hus I, Maciag E, Rolínski J. Znaczenie limfocytów Th17 w odpornósci przeciwnowotworowej. Postepy Hig Med Dosw 2010; 64: 244.
20. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744.
21. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198: 1951.
22. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461.
23. Gabay C, McInnes IB. The biological and clinical importance of the 'new generation'cytokines in rheumatic diseases. Arthr Res Ther 2009; 11: 230.
24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
25. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288.
26. Yee CS, Farewell VT, Isenberg DA, et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 2011; 50: 982-8.
27. Abrahamowicz M. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 1998; 25: 277-84.
28. Mancuso P, Calleri A, Cassi C, et al. Circulating endothelial cells as a novel marker of angiogenesis. Adv Exp Med Biol 2003; 522: 83.
29. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2000; 9: 3658-61.
30. Fornas O, Garcia J, Petriz J. Flowcytometry counting of CD34+ cells in whole blood. Nat Med 2000; 6: 833-6.
31. Wierzbowska A, Robak T, Krawczynska A, et al. Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients. Ann Hematol 2008; 87: 97-106.
32. Robak E, Kulczycka L, Sysa-Jedrzejowska A, et al. Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw 2007; 18: 181.
33. Betteli EKorn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453: 1051.
34. Iwakura Y, Nakae Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226: 57.
35. Vietinghoff S, Ley K. Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev 2010; 21: 463.
36. Chen DY, Chen YM, Wen MC, et al. The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 2012; 21: 1385.
37. Chen XQ, Yu YC, Deng HH, et al. Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. Clin Immunol 2010; 30: 221.
38. Zhao XF, Pan HF, Yuan H, et al. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep 2010; 37: 81.
39. Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Let 2004; 93: 39.
40. Takahashi H, Numasaki M, Lotze MT, Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Let 2005; 98: 189.
41. Numasaki M, Fukushi J, Ono M, Narula SK, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620.
42. Williams JM, Colman R, Brookes CJ, et al. Anti-endothelial cell antibodies from lupus patients bind to apoptotic endothelial cells promoting macrophage phagocytosis but do not induce apoptosis. Rheumatology 2005; 44: 879.
43. Song J, Park YB, Lee WK, et al. Clinical associations of anti-endothelial cell antibodies in patients with systemic lupus erythematosus. Rheumatol Int 2000; 20: 1.
44. D'Cruz DP, Houssiau FA, Ramirez G, et al. Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol 1991; 85: 254.
45. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42: 963.
46. Yamaguchi Y, Fujio K, Shoda H, et al. IL-17B and IL-17C Are associated with TNF a production and contribute to the exacerbation of inflammatory. Arthritis. J Immunol 2007; 179: 7128.
47. Shin MS, Lee N, Kang I. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin Rheumatol 2011; 23: 444.
48. Chang SH, Dong C. IL-17F: regulation, signaling and function in inflammation. Cytokine 2009; 46: 7.
49. Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL- 17F, and implications for receptor binding. Embo J 2001; 20: 5332.
50. Hedrich CM, Rauen T, Kis-Toth K, et al. cAMP-responsive element modulator _ (CREM_) suppresses IL-17F protein expression in T lymphocytes from patients with systemic lupus erythematosus (SLE). J Biol Chem 2012; 28: 4715.
51. Wong CK, Lit LCW, Tam LS, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol 2008; 3: 385.
52. Crispin JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 12: 8761.
53. Tong Z, Yang XO, Yan H, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One 2012; 7(4): e34959, Epub 2012.
54. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009; 183: 4169.